These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 18834945)

  • 21. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
    Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
    Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
    Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
    Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.
    Hanson LA; Bass AS; Gintant G; Mittelstadt S; Rampe D; Thomas K
    J Pharmacol Toxicol Methods; 2006; 54(2):116-29. PubMed ID: 16843688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Model-based evaluation of drug-induced QTc prolongation for compounds in early development.
    Dubois VF; Yu H; Danhof M; Della Pasqua O;
    Br J Clin Pharmacol; 2015 Jan; 79(1):148-61. PubMed ID: 25099645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
    Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
    J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monophasic action potential in anaesthetized guinea pigs as a biomarker for prediction of liability for drug-induced delayed ventricular repolarization.
    Tabo M; Kimura K; Ito S
    J Pharmacol Toxicol Methods; 2007; 55(3):254-61. PubMed ID: 17229580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired long QT syndrome from stress cardiomyopathy is associated with ventricular arrhythmias and torsades de pointes.
    Madias C; Fitzgibbons TP; Alsheikh-Ali AA; Bouchard JL; Kalsmith B; Garlitski AC; Tighe DA; Estes NA; Aurigemma GP; Link MS
    Heart Rhythm; 2011 Apr; 8(4):555-61. PubMed ID: 21146632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drugs, QT interval prolongation and ICH E14: the need to get it right.
    Shah RR
    Drug Saf; 2005; 28(2):115-25. PubMed ID: 15691222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
    Hondeghem LM
    J Cardiovasc Electrophysiol; 2006 Mar; 17(3):337-40. PubMed ID: 16643415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
    de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
    Haddad PM; Anderson IM
    Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL; Pollard CE; Hammond TG; Valentin JP
    J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD.
    Shah RR; Hondeghem LM
    Heart Rhythm; 2005 Jul; 2(7):758-72. PubMed ID: 15992736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ziprasidone in the management of schizophrenia : the QT interval issue in context.
    Taylor D
    CNS Drugs; 2003; 17(6):423-30. PubMed ID: 12697001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical QT safety assessment: cross-species comparisons and human translation from an industry consortium.
    Holzgrefe H; Ferber G; Champeroux P; Gill M; Honda M; Greiter-Wilke A; Baird T; Meyer O; Saulnier M
    J Pharmacol Toxicol Methods; 2014; 69(1):61-101. PubMed ID: 23689033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Corrected QT interval during treatment with methadone and buprenorphine--relation to doses and serum concentrations.
    Stallvik M; Nordstrand B; Kristensen Ø; Bathen J; Skogvoll E; Spigset O
    Drug Alcohol Depend; 2013 Apr; 129(1-2):88-93. PubMed ID: 23084592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measuring the risk of torsades de pointes: electrocardiographic evaluation of PNU-142093 in conscious cynomolgus non-human primates using restraint and non-restraint procedures.
    Bass AS; Hanson LA; Jackson TA
    J Pharmacol Toxicol Methods; 2009; 60(1):51-7. PubMed ID: 19447184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?
    Makaryus AN; Byrns K; Makaryus MN; Natarajan U; Singer C; Goldner B
    South Med J; 2006 Jan; 99(1):52-6. PubMed ID: 16466123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency of electrocardiogram testing among HIV-infected patients at risk for medication-induced QTc prolongation.
    Patel N; Veve M; Kwon S; McNutt LA; Fish D; Miller CD
    HIV Med; 2013 Sep; 14(8):463-71. PubMed ID: 23506263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of drug-induced QT interval prolongation in conscious rabbits.
    Kijtawornrat A; Ozkanlar Y; Keene BW; Roche BM; Hamlin DM; Hamlin RL
    J Pharmacol Toxicol Methods; 2006; 53(2):168-73. PubMed ID: 16290300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.